Yisheng biological pickup immune technology platform was supported by the project of major new drug development in the 13th five year plan

January 21, 2019 / Meitong news agency /-- Yisheng biopharmaceutical Co., Ltd (hereinafter referred to as Yisheng Biology) announced that recently the national health and Family Planning Commission officially approved the world's original pickup cell immune regulation technology platform developed by Yisheng biology to be listed in the national "13th five year plan" major new drug creation science and technology major special project This is the third time that the state has given support to the pickup technology project for the national major new drug creation project Support the industrial research and clinical breakthrough of this technology platform in new pharmaceutical materials Pica cell immunomodulatory technology platform is a new immunomodulatory activation technology independently developed by Yisheng biology company It can activate a variety of receptor signaling pathways, including TLR-3, MDA5 and rig- I et al Induce the human body to produce a series of cellular and humoral immune responses, improve the immune function of the body, so as to achieve the clinical efficacy of disease prevention and treatment, which has a broad application prospect in the clinical field of tumor and infectious diseases Relying on the technology platform, Yisheng biology has developed more than ten new immune drugs and innovative vaccine products At present, three products are in clinical development stage in more than 30 countries and regions, and more than 60 patent authorizations have been obtained The establishment of major special projects for major new drug creation technology in the 13th five year plan is an important layout for the country to implement the innovation driven development strategy It aims to promote the rapid development of the pharmaceutical industry by supporting the output of a number of major varieties, form a backbone enterprise with strong international competitiveness, improve the national drug independent innovation system, enhance the ability of independent innovation, and accelerate the transformation of China from imitation to creation and from medicine The transformation from a big pharmaceutical country to a powerful one The application of pica immunomodulatory technology in many fields has been supported by major national science and technology projects, which confirms the innovation ability and product potential of ebb in biomacromolecule immune products At the same time, the high attention and support of relevant national departments in this field fully reflects the major strategy of the state to encourage innovation and product internationalization of China's biopharmaceuticals, which is expected to We will accelerate the administrative review and commercialization of innovative biological products before they go on the market, and meet the needs of patients in China and the international market as soon as possible Lin Haixiang, the inventor of pica technology and senior scientist of Yisheng biology, said: "thank the country for its continuous support and investment in pica immune regulation technology over the years The R & D team of Yisheng biology has carried out a large number of preclinical and clinical research on the project, which lasted for more than 15 years More than 100 R & D personnel participated in the project, with R & D investment of more than 400 million yuan The technical achievements of the platform are the result of cooperation of more than 10 research institutions at home and abroad This project will further accelerate the industrialization process of pickup technology platform products and the expansion of new fields "   Mr Zhang Yi, chairman of Yisheng biology, said: "as a pharmaceutical enterprise deeply cultivating in the field of immune biological products, Yisheng biology has ushered in new development opportunities The new Piccard rabies vaccine products developed by relying on Piccard technology have received the positive evaluation of the World Health Organization (who) expert organization and the clinical approval documents of many countries, and the immune and anti-cancer products have obtained including the United States With the approval of several national regulatory agencies, including the FDA of China, the company will further increase investment in research and development of pickup technology, and actively promote clinical projects in many fields, such as immunoanticancer drugs, new vaccines, chronic hepatitis B immunotherapy We believe that in 3-5 years, many innovative biomacromolecule products will be approved and listed in many countries and regions to clinicians and patients around the world Provide safer and more effective treatment " In conclusion, Mr Zhang added: "I would like to thank research institutions from all over the world for their cooperation and contribution in the field of pickup technology and products over the years, including the State Food and Drug Administration of China, China food and Drug Control Institute, China CDC, the Pasteur Institute in France Institute), National Institutes of health of the United States, Wuxi Kant, Singapore Academy of Defense Science and technology, Chinese Academy of Sciences, qimr of Australia, Sun Yat sen University of China, aeras pharmaceutical company of the United States and Chinese Academy of Military Medical Sciences " Source: living organisms